CD33 Expression and Its Association With Gemtuzumab Ozogamicin Response: Results From the Randomized Phase III Children's Oncology Group Trial AAML0531

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Jessica PollardSoheil Meshinchi

Abstract

CD33 is variably expressed on acute myeloid leukemia (AML) blasts and is targeted by gemtuzumab ozogamicin (GO). GO has shown benefit in both adult and pediatric AML trials, yet limited data exist about whether GO response correlates with CD33 expression level. CD33 expression levels were prospectively quantified by multidimensional flow cytometry in 825 patients enrolled in Children's Oncology Group AAML0531 and correlated with response to GO. Patients with low CD33 expression (lowest quartile of expression [Q1]) had no benefit with the addition of GO to conventional chemotherapy (relapse risk [RR]: GO 36% v No-GO 34%, P = .731; event-free survival [EFS]: GO 53% v No-GO 58%, P = .456). However, patients with higher CD33 expression (Q2 to Q4) had significantly reduced RR (GO 32% v No-GO 49%, P < .001) and improved EFS (GO 53% v No-GO 41%, P = .005). This differential effect was observed in all risk groups. Specifically, low-risk (LR), intermediate-risk (IR), and high-risk (HR) patients with low CD33 expression had similar outcomes regardless of GO exposure, whereas the addition of GO to conventional chemotherapy resulted in a significant decrease in RR and disease-free survival (DFS) for patients with higher CD33 expression (LR...Continue Reading

References

Jul 4, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·E L SieversUNKNOWN Mylotarg Study Group
Nov 21, 2007·Leukemia Research·Denise A Wells, Michael R Loken
May 10, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Richard AplencUNKNOWN Children's Oncology Group
Apr 28, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Roland B WalterSoheil Meshinchi
Dec 22, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Alan K BurnettKeith Wheatley
Jan 31, 2012·Blood·Roland B WalterIrwin D Bernstein
Jun 26, 2012·Blood·Henrik HasleUNKNOWN Nordic Society of Paediatric Haematology and Oncology (NOPHO)
Aug 2, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Alan K BurnettDonald Milligan
May 9, 2014·Blood Reviews·George S LaszloRoland B Walter
May 29, 2014·Expert Opinion on Biological Therapy·Felicitas Thol, Richard F Schlenk

❮ Previous
Next ❯

Citations

Jun 14, 2017·Leukemia·C D GodwinR B Walter
Jul 16, 2016·American Journal of Hematology·Elihu Estey
Jul 3, 2017·Experimental Hematology·Alison A LaingKaren Keeshan
Feb 22, 2018·Biomedicines·Sarah K TasianSergio Rutella
Nov 28, 2017·Current Opinion in Pediatrics·Jessica B Foster, Shannon L Maude
Jun 24, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jatinder K LambaSoheil Meshinchi
Sep 26, 2017·Expert Opinion on Biological Therapy·Challice L BonifantStephen Gottschalk
Jun 7, 2018·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Eric J ChowElizabeth Fox
May 23, 2018·Expert Review of Clinical Pharmacology·Jeffrey Baron, Eunice S Wang
Jul 25, 2018·Future Oncology·Mohammed GbadamosiJatinder K Lamba
May 8, 2018·Journal of Pediatric Hematology/oncology·Michael J McNeilKatherine Tarlock
Sep 25, 2019·Leukemia & Lymphoma·Mansour AlfayezNaval Daver
Dec 19, 2019·Current Opinion in Pediatrics·Challice L Bonifant, Sarah K Tasian
Oct 19, 2016·Cytometry. Part a : the Journal of the International Society for Analytical Cytology·Michael R LokenDenise A Wells
Oct 13, 2017·Blood·Frederick R Appelbaum, Irwin D Bernstein
Sep 1, 2019·International Journal of Molecular Sciences·Peter ValentDominik Wolf
Dec 7, 2019·Hematology·Adam J Lamble, Sarah K Tasian
Dec 1, 2016·International Journal of Hematologic Oncology·Germana CastelliUgo Testa
Nov 27, 2019·Blood Advances·Adam J Lamble, Sarah K Tasian
Aug 28, 2020·Frontiers in Immunology·Lia WalcherUta Kossatz-Boehlert
Aug 13, 2020·International Journal of Molecular Sciences·Laurène FenwarthNicolas Duployez
Jun 3, 2018·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Dapeng ZhouTorsten Tonn
Sep 22, 2020·Minerva medica·MIchele GottardiClaudio Cerchione
Jun 12, 2019·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Katherine TarlockJessica A Pollard
Jan 14, 2021·Current Oncology Reports·Shannon E Conneely, Alexandra M Stevens
Dec 29, 2020·Future Oncology·Mohammed O GbadamosiJatinder K Lamba
Oct 23, 2020·Therapeutic Advances in Medical Oncology·Charalampos TheocharopoulosDimitrios C Ziogas
Feb 6, 2020·Journal of Medicinal Chemistry·Chiara BorsariMaria P Costi
Mar 22, 2020·Seminars in Oncology·Eric J ChowPaul C Nathan
Mar 25, 2021·Nature Reviews. Clinical Oncology·Elias JabbourHagop Kantarjian
Apr 2, 2021·CA: a Cancer Journal for Clinicians·Erin ButlerTheodore W Laetsch

❮ Previous
Next ❯

Related Concepts

Related Feeds

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.